Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer.

Priestman, T. J.; Baum, M; Jones, Vera E.; Forbes, John F.

doi:10.1136/bmj.1.6071.1248

Cited by 56 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of the present study indicate that patient-assessed QL scores are a promising prognostic predictor, in accordance with the findings of other researchers [6][7][8][9]11,12,22,23 who have conducted studies using Functional Living Index-Cancer (FLIC), 24 Linear Analog Self-Assessment (LASA), [25][26][27] or the Quality-of-Life Index (QLI) 26 as QL instruments for patients with various types of cancer.…”

Section: Discussionsupporting

confidence: 93%

The Prognostic Value of Quality-of-Life Scores: Preliminary Results of an Analysis of Patients with Breast Cancer

et al. 2000

View full text Add to dashboard Cite

This study was conducted to elucidate the prognostic value of patient-assessed quality-of-life (QL) scores in cancer patients. QL was assessed in 47 consecutive patients with advanced or end-stage breast cancer using the Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs (QOL-ACD). The data collected from 19 of the 47 patients, who completed QL questionnaires more than twice before dying of cancer, were analyzed. The relationships between the QL scores and subsequent survival were examined at two assessment points, being the first and last assessment points of each of the 19 patients; corresponding respectively to median survival times of 14 and 4 months. The prognostic significance of the changes in QL scores that occurred over 3 months before the last assessment point was also examined. At the last assessment point, the scores of the physical aspects of QL were significantly related to survival. The change in scores of both overall QL and the physical aspects of QL were also significant predictors of survival. On the other hand, neither the scores nor the change in scores of the psychological and social aspects of QL was significant. This study indicates that both QL scores and changes in QL scores are promising prognostic predictors.

show abstract

Section: Discussionsupporting

confidence: 93%

The Prognostic Value of Quality-of-Life Scores: Preliminary Results of an Analysis of Patients with Breast Cancer

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Patients self-reported their QL with five linear analogue self assessment (LASA) scales that measured physical well-being (PWB), mood, pain, nausea/vomiting and appetite (Priestman et al, 1977;Coates et al, 1993), and a single summative …”

Section: Ql Instrumentsmentioning

confidence: 99%

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer

et al. 2010

View full text Add to dashboard Cite

BACKGROUND: Baseline health-related quality of life (QL) is associated with survival in advanced breast cancer. We sought to identify patients who were less likely to respond to chemotherapy and at greater risk of toxicity on the basis of their QL. METHODS: We used data from three advanced breast cancer trials in which patients (n ¼ 378) were treated with cyclophosphamide, methotrexate and 5-fluouracil. Patients self-rated their QL using LASA scales for physical well-being (PWB), mood, pain, nausea/ vomiting, appetite and overall QL. Multivariable regression models were constructed to compare overall survival (OS), objective tumour response (OTR), adverse events (AEs) and weight loss according to grouped QL scores. RESULTS: Physical well-being, mood, appetite and overall QL were significant univariable predictors of OS. Physical well-being and appetite remained significant after adjustment for baseline biomedical factors. Poor PWB was associated with lower OTR (odds ratio (OR) ¼ 0.21, 95% confidence interval (CI) 0.09 -0.51), higher risk of non-haematological AEs (OR ¼ 3.26, 95% CI 1.49 -7.15) and greater risk of weight loss (OR 2.37, 95% CI 1.12 -5.01) compared with good PWB. CONCLUSIONS: In women with advanced breast cancer, PWB and appetite are predictors of chemotherapy response and toxicity as well as survival. Quality of life should be a routine clinical assessment to guide patient selection for chemotherapy and for stratification of patients in clinical trials.

show abstract

“…Antioestrogens, and in particular Tamoxifen, have been shown to be effective in advanced breast cancer (Priestman et al, 1977) and it is thus logical to perform clinical trials of these substances after surgery, either alone or with chemotherapy. N o such trials have as yet been reported.…”

Section: Adjuvant Systemic Therapymentioning

confidence: 99%

Early breast cancer: Part II. Management

Hughes¹,

Forbes²

1978

Journal of British Surgery

View full text Add to dashboard Cite

Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer.

Cited by 56 publications

References 3 publications

The Prognostic Value of Quality-of-Life Scores: Preliminary Results of an Analysis of Patients with Breast Cancer

The Prognostic Value of Quality-of-Life Scores: Preliminary Results of an Analysis of Patients with Breast Cancer

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer

Early breast cancer: Part II. Management

Contact Info

Product

Resources

About